S. Caleo

发表

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

R. Collins, G. Hankey, A. Keech, 1998, The New England journal of medicine.

Modelling approaches: the case of schizophrenia.

E. Buskens, F. D. de Charro, B. van Hout, 2008, PharmacoEconomics.

Economic Burden of Epilepsy among the Privately Insured in the US

H. Birnbaum, S. Caleo, J. Ivanova, 2012, PharmacoEconomics.

Modelling Approaches

E. Buskens, S. Caleo, F. D. Charro, 2012, PharmacoEconomics.

Cholesterol-Iowering therapywithpravastatin in patientswith averagecholesterol levelsandestablished ischaemicheartdisease: is it cost-effective?

P. Glasziou, A. Tonkin, R. Simes, 2002 .

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise

E. Buskens, B. van Hout, S. Caleo, 2008, Current medical research and opinion.

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis

J. Peuskens, S. Caleo, A. Mehnert, 2012, PharmacoEconomics.

Pharmacoeconomics 2008; 26 (8): 633-648

E. Buskens, S. Caleo, F. D. Charro, 2008 .

Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer.

T. Gorlia, M. Bolla, S. Caleo, 2002, Health economics.

Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis.

T. Gorlia, M. Bolla, S. Caleo, 2001, European journal of cancer.

An Economic Analysis of Psychotherapy for Borderline Personality Disorder Patients.

R. Meares, S. Caleo, Jane Hall, 2001, The journal of mental health policy and economics.

Statistical validation of the criteria for symptom remission in schizophrenia: Preliminary findings

Lawrence H. Yang, M. Opler, S. Caleo, 2007, BMC psychiatry.

Measles elimination: Costing of a national measles immunisation 'catch up' program, CHERE Project Report No 7

S. Caleo, Jane Hall, 1998 .

Assessing the unmet treatment need in partial‐onset epilepsy: Looking beyond seizure control

G. Montouris, B. Schmitz, S. Caleo, 2010, Epilepsia.

Cholesterol‐lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost‐effective?

H. White, P. Glasziou, A. Tonkin, 2002, The Medical journal of Australia.

Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923).

G. Giaccone, T. Gorlia, A. Ardizzoni, 2003, Annals of Oncology.

The cost-effectiveness of atypicals in the UK.

E. Buskens, F. D. de Charro, B. van Hout, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Clinical evaluation of community pharmacists' interventions

S. Caleo, S. Benrimoj, David M. Collins, 1996 .

Home or Hospital? An Evaluation of the Costs, Preferences, and Outcomes of Domiciliary Chemotherapy

S. Caleo, H. Gurney, P. Harnett, 2000, International journal of health services : planning, administration, evaluation.

Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States

Ying Qiu, David Mallett, H. Birnbaum, 2010, Epilepsia.